Breast cancer drug ineffective in treating squamous non-small cell lung cancer

Cancer History Project Conversation with The Cancer Letter

Lung cancer couldn’t slow down physician and athlete Lawrence Phillips

Something odd turned up in one of Lawrence Phillips’s routine health screenings in 2008.

September 06, 2024

By Deborah Doroshow and McKenzie Prillaman

FDA grants Imfinzi priority review and Breakthrough Therapy designation for limited-stage SCLC

FDA granted priority review for Imfinzi (durvalumab), AstraZeneca’s supplemental Biologics License Application, based on the results from the positive ADRIATIC phase III trial in patients with limited-stage small cell lung cancer whose disease has not progressed following platinum-based concurrent chemoradiotherapy.

September 06, 2024

Vol.50 No.33

Drugs & Targets

Daiichi Sankyo, Merck collaborate to develop and commercialize MK-6070, an investigational delta-like ligand 3 targeting T-cell engager

Daiichi Sankyo and Merck have expanded their existing global co-development and co-commercialization agreement for three investigational DXd antibody-drug conjugates to include Merck’s MK-6070, an investigational delta-like ligand 3 targeting T-cell engager.

August 09, 2024

Vol.50 No.32

In Brief

Pasi Jänne receives 2024 Bonnie J. Addario Lectureship Award

Pasi A. Jänne received the GO2 for Lung Cancer’s 2024 Bonnie J. Addario Lectureship Award.

August 02, 2024

Vol.50 No.31

Clinical Roundup

Vaping and smoking together increases lung cancer risk fourfold

People who both vape and smoke are four times more likely to develop lung cancer than people who just smoke, according to a new study published by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and College of Public Health.

August 02, 2024

Vol.50 No.31

Clinical Roundup

Ninety-three percent of oncologists adjust treatment recommendations with OncoHost’s PROphetNSCLC test

OncoHost, a technology company, announced the publication of a study in Clinical Lung Cancer demonstrating the impact of its PROphetNSCLC test on first-line treatment decisions for metastatic non-small cell lung cancer patients.

August 02, 2024

Vol.50 No.31

Breast cancer drug ineffective in treating squamous non-small cell lung cancer

YOU MAY BE INTERESTED IN

Lung cancer couldn’t slow down physician and athlete Lawrence Phillips

FDA grants Imfinzi priority review and Breakthrough Therapy designation for limited-stage SCLC

Daiichi Sankyo, Merck collaborate to develop and commercialize MK-6070, an investigational delta-like ligand 3 targeting T-cell engager

Pasi Jänne receives 2024 Bonnie J. Addario Lectureship Award

Vaping and smoking together increases lung cancer risk fourfold

Ninety-three percent of oncologists adjust treatment recommendations with OncoHost’s PROphetNSCLC test

Renew today!

Subscriber content

Can you spare 10 minutes to complete a survey?

Login